Innate Adds To IO Pipeline With Novo's First-In-Class Anti-C5aR Candidate
Phase I candidate already tested in rheumatoid arthritis could be used to optimize the activity of T cells and NK cells in the tumor microenvironment, either in combination with checkpoint inhibitors or as a solo agent.
You may also be interested in...
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Bristol says its combination development program for lirilumab - licensed from Innate Pharma in 2011 – remains unaffected by news the anti-KIR checkpoint inhibitor failed in a Phase II trial in elderly patients with acute myeloid leukemia as a maintenance monotherapy.
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.